Market capitalization | $236.64m |
Enterprise Value | $158.26m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 3.11 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-151.32m |
Free Cash Flow (TTM) Free Cash Flow | $-113.02m |
Cash position | $87.95m |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
10 Analysts have issued a Biomea Fusion Inc forecast:
10 Analysts have issued a Biomea Fusion Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -2.35 -2.35 |
31%
31%
|
|
EBITDA | -149 -149 |
33%
33%
|
EBIT (Operating Income) EBIT | -151 -151 |
31%
31%
|
Net Profit | -144 -144 |
34%
34%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. The company was founded by Thomas Butler and Ramses Erdtmann in August 2017 and is headquartered in Redwood City, CA.
Head office | United States |
CEO | Tom Butler |
Employees | 103 |
Founded | 2017 |
Website | biomeafusion.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.